LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

Search

Immunocore Holdings PLC ADR

Aperta

36.35 -0.85

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

34.7

Massimo

36.59

Metriche Chiave

By Trading Economics

Entrata

-15M

-10M

Vendite

4.1M

98M

Margine di Profitto

-10.514

Dipendenti

493

EBITDA

-11M

-15M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+58.9% upside

Dividendi

By Dow Jones

Utili prossimi

4 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-11M

1.6B

Apertura precedente

37.2

Chiusura precedente

36.35

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

Immunocore Holdings PLC ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 set 2025, 23:59 UTC

Acquisizioni, Fusioni, Takeovers

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 set 2025, 22:02 UTC

I principali Market Mover

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 set 2025, 17:01 UTC

I principali Market Mover

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 set 2025, 17:01 UTC

I principali Market Mover

Tron Shares Rise After New Investment From Bravemorning

8 set 2025, 16:14 UTC

I principali Market Mover

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 set 2025, 16:13 UTC

I principali Market Mover

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 set 2025, 23:12 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

8 set 2025, 23:12 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 set 2025, 23:12 UTC

Discorsi di Mercato

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 set 2025, 22:56 UTC

Discorsi di Mercato

Worst May Be Over for New Zealand Retailers -- Market Talk

8 set 2025, 22:23 UTC

Discorsi di Mercato

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 set 2025, 21:51 UTC

Discorsi di Mercato

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 set 2025, 21:47 UTC

I principali Market Mover

Microsoft Signs $17.4B AI Deal With Nebius

8 set 2025, 21:33 UTC

Acquisizioni, Fusioni, Takeovers

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 set 2025, 21:20 UTC

Acquisizioni, Fusioni, Takeovers

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 set 2025, 21:19 UTC

Acquisizioni, Fusioni, Takeovers

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 set 2025, 21:18 UTC

Acquisizioni, Fusioni, Takeovers

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 set 2025, 20:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

8 set 2025, 19:33 UTC

Discorsi di Mercato

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 set 2025, 19:22 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 set 2025, 19:02 UTC

Discorsi di Mercato

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 set 2025, 18:24 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

8 set 2025, 18:24 UTC

Discorsi di Mercato

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 set 2025, 17:29 UTC

Discorsi di Mercato

Mexican Inflation Seen Little Changed in August -- Market Talk

8 set 2025, 16:59 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 set 2025, 16:36 UTC

Discorsi di Mercato

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 set 2025, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

8 set 2025, 16:16 UTC

Utili

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 set 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

8 set 2025, 16:04 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Immunocore Holdings PLC ADR Previsione

Obiettivo di Prezzo

By TipRanks

58.9% in crescita

Previsioni per 12 mesi

Media 59.11 USD  58.9%

Alto 100 USD

Basso 34 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Immunocore Holdings PLC ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

7

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

27.895 / 30.16Supporto e resistenza

A breve termine

Weak Bearish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

Weak Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
help-icon Live chat